BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 917456)

  • 21. Immunotherapy for malignant melanoma with a tumor cell vaccine.
    Slingluff CL; Seigler HF
    Ann Plast Surg; 1992 Jan; 28(1):104-7. PubMed ID: 1642395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 25. Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
    Currie GA; McElwain TJ
    Br J Cancer; 1975 Feb; 31(2):143-56. PubMed ID: 1164466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunotherapy with BCG as coadjuvant in the management of malignant melanomas].
    Céspedes de Gómez MM; Aguilar Velázquez G; Valles de Cortés Y
    Alergia; 1980 Apr; 27(2):69-86. PubMed ID: 7416444
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
    Hedley DW; McElwain TJ; Currie GA
    Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of recurrent melanoma of the extremity.
    Shingleton WW; Seigler HF; Stocks LH; Downs RW
    Cancer; 1975 Mar; 35(3):574-9. PubMed ID: 234293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of malignancy in humans. Current status.
    Holmes EC; Eilber FR; Morton DL
    JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunotherapy].
    Lejeune FJ; Bernheim JL; Vanwijck R
    Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
    [No Abstract]   [Full Text] [Related]  

  • 32. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
    Mavligit G; Gutterman JU; McBride C; Hersh EM
    Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE; Peter HH; Schultheis W; Deicher H
    Tumori; 1977; 63(3):303-7. PubMed ID: 898298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cancer immunotherapy in dermatological view (author's transl)].
    Lübbe D; Gstöttner R
    Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer immunotherapy.
    Richman SP; Gutterman JU; Hersh EM
    Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 38. Specific active immunotherapy for melanoma.
    Seigler HF; Cox E; Mutzner F; Shepherd L; Nicholson E; Shingleton WW
    Ann Surg; 1979 Sep; 190(3):366-72. PubMed ID: 485611
    [No Abstract]   [Full Text] [Related]  

  • 39. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
    Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
    Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.